NCT04715932 - Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

May 25, 2021

Study Completion Date

June 7, 2021

Conditions

Covid19AnosmiaFeverCoughShortness of BreathSore ThroatNauseaVomitingHeadacheMuscle WeaknessPain, MusclePain, ChestPain, JointPain, AbdominalPainIrritable MoodConfusion

Interventions

DRUG

Hesperidin

Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.

DRUG

Placebo

Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.

Trial Locations (1)

H1T1C8

Montreal Heart Institute, Montreal